Til on Bioeconhttps://en.bioecon.ru/technologies/til/Recent content in Til on BioeconHugoen-USSat, 11 Jul 2026 14:19:14 +0700TIL therapy (tumor-infiltrating lymphocytes)https://en.bioecon.ru/technology/til-therapy/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/til-therapy/TIL therapy — autologous tumor-infiltrating T-cells with polyclonal specificity; the first approved drug Lifileucel (Amtagvi, Iovance, FDA 2024) is a breakthrough in metastatic melanoma.